Abstract
Mucosal melanomas are rare tumors which most commonly arise in the upper aerodigestive tract (oral cavity, nasal cavity, and sinuses), anorectum, and female genital tract. Compared to cutaneous melanomas, far less is known about the pathogenesis, natural history, and management of mucosal melanomas. At presentation, mucosal melanomas are characteristically more advanced and associated with poorer outcomes than cutaneous melanomas. The primary treatment modality is complete surgical excision, but due to the anatomical location and advanced stage at presentation, complete removal may not be possible. As the overwhelming majority of patients with locally advanced tumors will die of metastatic disease, highly morbid and/or extensive procedures with major impact on quality of life may not be justified. For patients with advanced disease, immunotherapy with anti PD-1 therapy should be considered and similarly for the small proportion of patients with a c-kit mutation targeted therapy with imatinib may be worthwhile. Unfortunately, the results of treatment for advanced disease do not match those seen for cutaneous melanoma. In this chapter, we review the clinical and pathologic features of mucosal melanomas in general and provide a more detailed discussion concerning the presentation and management of tumors originating in specific anatomical locations. Management of advanced disease is considered separately.
Similar content being viewed by others
References
Alawi F (2013) Pigmented lesions of the oral cavity: an update. Dent Clin N Am 57:699–710
Ano-uro-genital Mucosal Melanoma Guideline Development Group Melanoma Focus Ano-uro-genital Mucosal Melanoma Guidelines. https://melanomafocus.com/activities/mucosal-guidelines. Accessed 23 July 2018
Ascierto PA, Simeone E, Sileni VC et al (2014) Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 12:116
Avril MF, Aamdal S, Grob JJ et al (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22:1118–1125
Bai X, Mao LL, Chi ZH et al (2017) BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma. Neoplasma 64:626–632
Ballantyne AJ (1970) Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. Am J Surg 120:425–431
Bishop KD, Olszewski AJ (2014) Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis. Int J Cancer 134:2961–2971
Cancer Council Australia Melanoma Guidelines Working Party Clinical practice guidelines for the diagnosis and management of melanoma. https://wiki.cancer.org.au/australia/Guidelines:Melanoma. Accessed 8 Feb 2018
Carvajal RD, Antonescu CR, Wolchok JD et al (2011) KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327–2334
Chae WY, Lee JL, Cho D-H et al (2016) Preliminary suggestion about staging of anorectal malignant melanoma may be used to predict prognosis. Cancer Res Treat 48:240–249
Chang AE, Karnell LH, Menck HR (1998) The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 83:1664–1678
Chen H, Cai Y, Liu Y et al (2016) Incidence, surgical treatment, and prognosis of anorectal melanoma from 1973 to 2011: a population-based SEER analysis. Medicine (Baltimore) 95:e2770
Ciarrocchi A, Pietroletti R, Carlei F, Amicucci G (2017) Extensive surgery and lymphadenectomy do not improve survival in primary melanoma of the anorectum: results from analysis of a large database (SEER). Color Dis 19:158–164
Cui C, Mao L, Chi Z et al (2013) A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther 21:1456–1463
Cui C, Lian B, Zhou L et al (2018) Multifactorial analysis of prognostic factors and survival rates among 706 mucosal melanoma patients. Ann Surg Oncol 25(8):2184–2192
Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147
Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340–4346
D’Angelo SP, Larkin J, Sosman JA et al (2017) Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol 35:226–235
de Hullu JA, Hollema H, Hoekstra HJ et al (2002) Vulvar melanoma: is there a role for sentinel lymph node biopsy? Cancer 94:486–491
Frumovitz M, Etchepareborda M, Sun CC et al (2010) Primary malignant melanoma of the vagina. Obstet Gynecol 116:1358–1365
Gadducci A, Carinelli S, Guerrieri ME, Aletti GD (2018) Melanoma of the lower genital tract: prognostic factors and treatment modalities. Gynecol Oncol 150:180–189
Gavriel H, McArthur G, Sizeland A, Henderson M (2011) Review: mucosal melanoma of the head and neck. Melanoma Res 21:257–266
Gershenwald JE, Scolyer RA, Hess KR et al (2017a) Melanoma of the skin. In: Amin M, Edge SB, Greene FL et al (eds) AJCC cancer staging manual, 8th edn. Springer, Switzerland, pp 563–585
Gershenwald JE, Scolyer RA, Hess KR et al (2017b) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(6):472–492
Guo J, Si L, Kong Y et al (2011) Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29:2904–2909
Guo J, Sheng X, Si L, et al (2018) A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma. J Clin Oncol (suppl–abstr 9528)
Hicks CW, Pappou EP, Magruder JT et al (2014) Clinicopathologic presentation and natural history of anorectal melanoma: a case series of 18 patients. JAMA Surg 149:608–611
Hodi FS, Corless CL, Giobbie-Hurder A et al (2013) Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 31:3182–3190
Irvin WPJ, Legallo RL, Stoler MH et al (2001) Vulvar melanoma: a retrospective analysis and literature review. Gynecol Oncol 83:457–465
Jethanamest D, Vila PM, Sikora AG, Morris LGT (2011) Predictors of survival in mucosal melanoma of the head and neck. Ann Surg Oncol 18:2748–2756
Kelly P, Zagars GK, Cormier JN et al (2011) Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: a 20-year experience. Cancer 117:4747–4755
Krengli M, Masini L, Kaanders JHAM et al (2006) Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study. Int J Radiat Oncol Biol Phys 65:751–759
Kuk D, Shoushtari AN, Barker CA et al (2016) Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist 21:848–854
Larsson KB, Shaw HM, Thompson JF et al (1999) Primary mucosal and glans penis melanomas: the Sydney Melanoma Unit experience. Aust N Z J Surg 69:121–126
Lawaetz M, Birch-Johansen F, Friis S et al (2016) Primary mucosal melanoma of the head and neck in Denmark, 1982–2012: demographic and clinical aspects. A retrospective DAHANCA study. Acta Oncol 55:1001–1008
Lewis MG, Martin JA (1967) Malignant melanoma of the nasal cavity in Ugandan Africans. Relationship of ectopic pigmentation. Cancer 20:1699–1705
Lian B, Si L, Cui C et al (2013) Phase II randomized trial comparing high-dose IFN-alpha2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res 19:4488–4498
Lian B, Cui C, Song X, et al (2017a) Phase III randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma. J Clin Oncol (suppl–abstr 9589)
Lian B, Cui CL, Zhou L et al (2017b) The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients. Ann Oncol 28:868–873
Lopez F, Rodrigo JP, Cardesa A et al (2016) Update on primary head and neck mucosal melanoma. Head Neck 38:147–155
Lund VJ, Howard DJ, Harding L, Wei WI (1999) Management options and survival in malignant melanoma of the sino-nasal mucosa. Laryngoscope 109:208–211
Matsuda A, Miyashita M, Matsumoto S et al (2015) Abdominoperineal resection provides better local control but equivalent overall survival to local excision of anorectal malignant melanoma: a systematic review. Ann Surg 261:670–677
Merkel EA, Gerami P (2017) Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular features. Lab Investig 97:630–635
Michel J, Perret-Court A, Fakhry N et al (2014) Sino-nasal mucosal melanomas: the prognostic value of tumor classifications. Head Neck 36:311–316
Moreno M, Roberts D, Kupferman M et al (2010) Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the MD Anderson Cancer Center. Cancer 116:2215–2223
Moxley KM, Fader AN, Rose PG et al (2011) Malignant melanoma of the vulva: an extension of cutaneous melanoma? Gynecol Oncol 122:612–617
Nagarajan P, Curry JL, Ning J et al (2017) Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: a retrospective review of 100 cases. Clin Cancer Res 23:2093–2104
Nilsson PJ, Ragnarsson-Olding BK (2010) Importance of clear resection margins in anorectal malignant melanoma. Br J Surg 97:98–103
Owens JM, Roberts DB, Myers JN (2003) The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg 129:864–868
Perez DR, Trakarnsanga A, Shia J et al (2013) Locoregional lymphadenectomy in the surgical management of anorectal melanoma. Ann Surg Oncol 20:2339–2344
Phillips GL, Bundy BN, Okagaki T et al (1994) Malignant melanoma of the vulva treated by radical hemivulvectomy. A prospective study of the Gynecologic Oncology Group. Cancer 73:2626–2632
Piura B (2008) Management of primary melanoma of the female urogenital tract. Lancet Oncol 9:973–981
Postow MA, Luke JJ, Bluth MJ et al (2013) Ipilimumab for patients with advanced mucosal melanoma. Oncologist 18:726–732
Ragnarsson-Olding BK, Nilsson BR, Kanter-Lewensohn LR et al (1999) Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival. Cancer 86:1285–1293
Ragnarsson-Olding BK, Nilsson PJ, Olding LB, Nilsson BR (2009) Primary ano-rectal malignant melanomas within a population-based national patient series in Sweden during 40 years. Acta Oncol 48:125–131
Saida T, Kawachi S, Takata M et al (2004) Histopathological characteristics of malignant melanoma affecting mucous membranes: a unifying concept of histogenesis. Pathology 36:404–413
Scotto J, Fraumeni JFJ, Lee JA (1976) Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. JNCI 56:489–491
Seifried S, Haydu LE, Quinn MJ et al (2015) Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinico-pathologic analysis of 85 cases. Ann Surg Oncol 22:1959–1956
Shoushtari AN, Bluth MJ, Goldman DA et al (2017) Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. Melanoma Res 27:57–64
Stárek I, Koranda P, Benes P (2006) Sentinel lymph node biopsy: a new perspective in head and neck mucosal melanoma? Melanoma Res 16:423–427
Sugiyama VE, Chan JK, Shin JY et al (2007) Vulvar melanoma: a multivariable analysis of 644 patients. Obstet Gynecol 110:296–301
Takagi M, Ishikawa G, Mori W (1974) Primary malignant melanoma of the oral cavity in Japan. With special reference to mucosal melanosis. Cancer 34:358–370
Tchelebi L, Guirguis A, Ashamalla H (2016) Rectal melanoma: epidemiology, prognosis, and role of adjuvant radiation therapy. J Cancer Res Clin Oncol 142:2569–2575
Tcheung WJ, Selim MA, Herndon JE 2nd et al (2012) Clinicopathologic study of 85 cases of melanoma of the female genitalia. J Am Dermatol 67:598–605
Temam S, Mamelle G, Marandas P et al (2005) Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer 103:313–319
van Geel AN, den Bakker MA, Kirkels W et al (2007) Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature. Urology 70:143–147
Vaysse C, Pautier P, Filleron T et al (2013) A large retrospective multicenter study of vaginal melanomas: implications for new management. Melanoma Res 23:138–146
Verschraegen CF, Benjapibal M, Supakarapongkul W et al (2001) Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later. Int J Gynecol Cancer 11:359–364
Yii NW, Eisen T, Nicolson M et al (2003) Mucosal malignant melanoma of the head and neck: the Marsden experience over half a century. Clin Oncol (R Coll Radiol) 15:199–204
Zimmer L, Eigentler TK, Kiecker F et al (2015) Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. J Transl Med 13:351
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this entry
Cite this entry
Henderson, M.A. et al. (2019). Mucosal Melanoma. In: Balch, C., et al. Cutaneous Melanoma. Springer, Cham. https://doi.org/10.1007/978-3-319-46029-1_15-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-46029-1_15-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-46029-1
Online ISBN: 978-3-319-46029-1
eBook Packages: Springer Reference MedicineReference Module Medicine